Containing Polysaccharides (e.g., Sugars) Patents (Class 424/493)
-
Publication number: 20110229580Abstract: Disclosed herein are compositions, methods and kits for a microsphere with one or more entrapped nanoparticles. The method of preparation comprises atomizing a suspension comprising a polysaccharide and one or more nanoparticles into a solution comprising a cross linking agent.Type: ApplicationFiled: March 22, 2010Publication date: September 22, 2011Inventors: Rohit SRIVASTAVA, Abhijeet Balwantrao Joshi, R. Keerthi PRASAD
-
Patent number: 8021684Abstract: The present invention relates to a haemostatic composition comprising a biologically absorbable material and hyaluronic acid or a derivative thereof, methods of producing such compositions and the use of these compositions. In particular the method of producing said haemostatic composition comprises treating it with dry heat at a temperature between 110-200° C.Type: GrantFiled: July 7, 2005Date of Patent: September 20, 2011Assignee: Ferrosan Medical Devices A/SInventors: Lene Møller, Kristina Devantier, Trine Wulff, Mads Christian Sabra
-
Publication number: 20110223256Abstract: A method for suspending microparticulated water insoluble bioactive compound in a beverage by incorporating solubilized or dispersed microparticulated compound and at least one dispersion stabilizer into a beverage. A composition comprising solubilized or dispersed microparticulated water insoluble bioactive compound and a dispersion stabilizer agent.Type: ApplicationFiled: February 28, 2011Publication date: September 15, 2011Applicant: STOKELY-VAN CAMP, INC.Inventors: Naijie Zhang, Vincent E.A. Rinaldi, Peter S. Given, JR.
-
Patent number: 8017152Abstract: Process for producing parenterally administrable cores. The cores are intermediates suitable for manufacturing sustained release preparations. Microcapsules incorporating a core and a shell and pharmaceutical compositions incorporating such cores and microcapsules are also provided.Type: GrantFiled: May 24, 2006Date of Patent: September 13, 2011Assignee: Stratosphere Pharma ABInventors: Nils Ove Gustafsson, Monica Jonsson, Timo Laakso
-
Patent number: 8012507Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.Type: GrantFiled: October 29, 2007Date of Patent: September 6, 2011Assignee: MedImmune Vaccines, Inc.Inventors: Vu Truong-Le, Binh Pham
-
Publication number: 20110212181Abstract: Neutrophil elastase (NE) is a protease secreted by neutrophils during inflammation. Aberrant expression of NE such as in chronic respiratory inflammatory diseases, results in tissue destruction and decline in lung function. Compositions including an NE-targeting agent that targets the pathologic elements of respiratory inflammation are provided. Non-anticoagulant heparin derivatives or fragments are exemplary NE-targeting agents. The compositions preferably include a carrier, such as chitosan, to facilitate delivery of the active agent. Methods of manufacturing non-anticoagulant heparin are also provided. Methods of administering the disclosed compositions to treat respiratory diseases are also disclosed. In preferred methods, an effective amount of the pharmaceutical composition is administered to subject in need thereof to reduce, inhibit, or alleviate one or more symptoms of chronic respiratory inflammation.Type: ApplicationFiled: February 25, 2011Publication date: September 1, 2011Applicant: The University of Hong KongInventors: Daisy Kwok Yan Shum, Mary Sau Man Ip, Chi Hang Chan, Valeria On Yue Leung
-
Publication number: 20110212164Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Pol, Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Pol, Gag- and/or Env-containing proteins are also described.Type: ApplicationFiled: May 2, 2011Publication date: September 1, 2011Applicant: Novartis Vaccines & Diagnostics, Inc.Inventors: Susan BARNETT, Jan Zur Megede
-
Publication number: 20110206772Abstract: The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.Type: ApplicationFiled: May 28, 2009Publication date: August 25, 2011Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. Kaplan, Bruce Panilaitis, Michael Mercaldi, Hanna Dams-Kozlowska
-
Encapsulated functional fine particle composition capable of spraying and preparation method thereof
Publication number: 20110206771Abstract: Provided is an encapsulated functional fine particle composition capable of spraying that is useful for hemostasis and wound protection and allows a patient to treat the wound by oneself. Additionally, the composition can be rapidly applied on a large wound during an operation using an air gun in case of in-vivo application and shows prompt hemostasis.Type: ApplicationFiled: October 30, 2009Publication date: August 25, 2011Applicant: GENEWEL CO., LTDInventors: Jin-suk Choi, Young-woo Lee, Jun-ho Kim, Eun-young Shim -
Patent number: 7993677Abstract: Stable and uniform distribution of gel beads or other particulate material, dispersed in a liquid medium can be obtained by including a density-reducing agent within the gel beads to provide the particle with a desired bulk density, for example a density close to that of the disperse liquid medium. Suitable density control can prevent migration due to gravity leading to settling in storage. Gel beads formulated with agar are suitable for use in cosmetics and for inclusion in cosmetics formulating processes which may employ modestly elevated temperatures. Attractive and novel cosmetics bead suspensions are described. Additional to cosmetics, pharmaceutical, foodstuff and other applications are disclosed. Examples of suitable density-reducing agents include very low density hollow polymeric microspheres and temperature-sensitive expandable thermoplastic microspheres.Type: GrantFiled: November 26, 2003Date of Patent: August 9, 2011Assignee: Kobo Products, Inc.Inventors: Li Ding, Stephanie Morar, David Schlossman
-
Publication number: 20110189299Abstract: The invention provides a pharmaceutical composition that can be used for efficient administration of low-molecular weight drugs and polymeric compounds such as peptides and proteins by methods other than injection, as well as a method for producing the composition. The pharmaceutical composition is for transmucosal administration and comprises (a) a drug having a positive or negative charge at a predetermined pH, (b) a pharmaceutically acceptable small particle and (c) a pharmaceutically acceptable surface-coating polymer capable of being electrically charged at the pH, wherein the surface of the small particle is coated by the surface-coating polymer, the drug is immobilized on the surface of the small particle via the surface-coating polymer, and a complex is formed by a noncovalent interaction between the small particle and the surface-coating polymer and a concurrent electrostatic interaction between the surface-coating polymer and the drug.Type: ApplicationFiled: July 1, 2009Publication date: August 4, 2011Applicant: NITTO DENKO CORPORATIONInventors: Katsuyuki Okubo, Chieko Kitaura, Kenjiro Minomi, Elizabeth Pearson, Clive J. Roberts, Martyn C. Davies, Snjezana Stolnik-Trenkic, Lisbeth Illum
-
Publication number: 20110177153Abstract: The present invention relates to a targeted magnetic nanoparticle drug and the preparation method thereof. The targeted magnetic nanoparticle drug comprises an effector molecule and a guidance molecule in a weight ratio of 1:0.0001-0.20. The aforesaid effector molecule is a magnetic particle, with a particle size of not more than 1000 nm and a specific adsorption rate (SAR) of 10-7000 W/gFe. The aforesaid guidance molecule comprises an antibody, a ligand or a magnetic particle. The particle size of the aforesaid targeted drug is 2-1000 nm. The targeted magnetic nanoparticle drug is prepared by coupling a magnetic particle and a guidance molecule in a weight ratio of 1:0.0001-0.20 in water, organic or inorganic substance or the mixed solution thereof. The resultant targeted magnetic nanoparticle drug can realize targeted magnetic hyperthermia treatment and targeted magnetic thermoablation treatment and prevention on the tumors, and effectively kill the cancer cells, and cure the malignant tumors.Type: ApplicationFiled: October 20, 2006Publication date: July 21, 2011Applicant: Hong ZhuInventor: Hong Zhu
-
Publication number: 20110171314Abstract: The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided.Type: ApplicationFiled: March 30, 2007Publication date: July 14, 2011Inventors: Anthony T. CHEUNG, Eric C. Hsu
-
Patent number: 7976825Abstract: Macromolecular contrast agents for magnetic resonance imaging are described. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents are described. Nanoparticles (NP) have been constructed by self-assembling of chitosan (CHIT) as polycation and poly-gamma glutamic acids (PGA) as polyanion. NP's are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity. Folic acid (FA) is linked to the NP's to produce NP-FA bioconjugates that can be used for targeted in vitro delivery to a human cancer cell line.Type: GrantFiled: December 8, 2008Date of Patent: July 12, 2011Inventors: Janos Borbely, Magdolna Bodnar, John F Hartmann, Istvan Hajdu, Jozsef Kollar, Gyorgy Vamosi
-
Patent number: 7977369Abstract: Methods for treating bladder cancer comprising intravesicular administration of a stabilized pharmaceutical formulation comprising 5-(1-aziridinyl)-3-(hydroxymethyl)-2-[(E)-3-hydroxyprop-1-enyl]-1-methyl-1H-indole-4,7-dione (EO9). More specifically, the stabilized pharmaceutical formulation is instilled in the bladder for a time sufficient to treat the cancer.Type: GrantFiled: March 21, 2008Date of Patent: July 12, 2011Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen
-
Publication number: 20110165256Abstract: In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent.Type: ApplicationFiled: July 8, 2010Publication date: July 7, 2011Inventors: Neil P. DESAI, Patrick SOON-SHIONG
-
Patent number: 7960330Abstract: Microcapsule for use in a liquid detergent composition, the microcapsule having a core and a polymeric polyanion-polycation complex shell wherein the polyanion component is capable of gelling in the presence of calcium and has a storage modulus when gelled with 0.05 moles/litre of calcium of less than about 150 Pa at an angular frequency of about 0.5 rad/s and a polyanion concentration of about 3.8% by weight at 25° C. The invention also relates to a process for making the microcapsules, liquid detergents comprising the microcapsules and cleaning methods using the liquid detergents.Type: GrantFiled: August 23, 2005Date of Patent: June 14, 2011Assignee: The Procter & Gamble CompanyInventors: Jean-Pol Boutique, Walter August Maria Broeckx, Jonathan Richard Stonehouse, Walter Franciscus Joanna Vanderveken, Anna-Louise McConnachie
-
Patent number: 7951390Abstract: A slow-release microcapsule composition for the safe delivery of agriculturally active material is formed using an encapsulation process. A microencapsulated suspension of agriculturally active material includes an encapsulating agent formed from a graft copolymer of starch and at least on vinyl monomer.Type: GrantFiled: December 28, 2006Date of Patent: May 31, 2011Assignee: United Phosphorus, Ltd.Inventors: Prakash Mahadev Jadhav, Jaidev Rajnikant Shroff, Shirsat Rajan Ramakant, Ahire Dnyaneshwar Laxman
-
Patent number: 7947257Abstract: Compositions are provided for the intranasal administration of granisetron or a pharmaceutically acceptable salt thereof. Preferred compositions are in the form of an aqueous solution. Optionally, the compositions comprise chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention of nausea and/or vomiting.Type: GrantFiled: December 3, 2004Date of Patent: May 24, 2011Assignee: Archimedes Development LimitedInventors: Peter James Watts, Alan Smith, Jonathan Castile
-
Publication number: 20110111041Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.Type: ApplicationFiled: December 29, 2010Publication date: May 12, 2011Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid, Toby Hulf
-
Publication number: 20110111021Abstract: The present invention provides a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active ingredient, and a compartment containing an HMG-CoA reductase inhibitor as a pharmacologically active ingredient, wherein one compartment is a prior-release compartment and the other compartment is a delayed-release compartment. The combination preparation of the present invention can deliver a renin inhibitor and an HMG-CoA reductase inhibitor with a time interval at a specific speed, thus reducing undesirable side-effects, improving the drug efficacy and promoting the patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndromes, cardiovascular diseases, renal diseases and the like, as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.Type: ApplicationFiled: February 23, 2009Publication date: May 12, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Jaw Woon Son, Jin Wook Kim
-
Publication number: 20110111042Abstract: The invention provides a microcapsule having a shell and a liquid core incorporating a self-microemulsifying system or a microemulsion, wherein the core comprises a lipophilic substance, at least one surfactant, an active agent, a gelling agent and optionally a cosolvent. Furthermore, a method for producing such microcapsules and pharmaceutical formulations comprising such microcapsules is provided.Type: ApplicationFiled: April 21, 2009Publication date: May 12, 2011Applicant: LEK PHARMACEUTICALS D.D.Inventors: Janez Kerc, Miha Homar, Mirjana Gasperlin
-
Patent number: 7939105Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: November 19, 1999Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Patent number: 7939106Abstract: Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less.Type: GrantFiled: May 23, 2003Date of Patent: May 10, 2011Assignee: Jagotec AGInventors: Indu Parikh, Awadhesh K. Mishra, Robert Donga, Michael G. Vachon
-
Publication number: 20110104283Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.Type: ApplicationFiled: October 27, 2010Publication date: May 5, 2011Inventors: Shaker A. Mousa, Mohammed H. Qari, Mohammed S. Ardawi
-
Publication number: 20110097385Abstract: A method of lowering blood glucose in a mammal includes administering orally or by injection or inhalation a therapeutically effective amount of crystallized dextran microparticles and insulin to the mammal to lower blood glucose of the mammal. The composition may be a one phase or a structured multi-phase composition for controlled release of insulin or other therapeutic agents.Type: ApplicationFiled: March 4, 2004Publication date: April 28, 2011Applicant: TTDC BIO L.P.Inventor: Vladimir Sabetsky
-
Patent number: 7928111Abstract: The present invention provides compounds including substituted thienopyrimidinone derivatives of Formula (IIc) as ligands for modulating chemosensory receptors: These compounds are useful as sweet taste enhancers in comestible or medicinal compositions. The present invention also provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.Type: GrantFiled: August 8, 2007Date of Patent: April 19, 2011Assignee: Senomyx, Inc.Inventors: Catherine Tachdjian, Xiao-Qing Tang, Sara Werner, Marketa Rinnova, Qing Chen, Guy Servant, Xiaodong Li, Feng Zhang, Haitian Liu, Albert Zlotnik, Mark Zoller, Boris Klebansky, Richard Fine, Xinshan Kang
-
Patent number: 7927628Abstract: The present invention provides sustained-release preparations from which a pharmacologically active substance can be released over a long time and a process for producing the same. Such a sustained-release preparation is produced by melt-granulating a low-melting-point substance and a pharmacologically active substance and melt-coating the surface of the thus obtained particles with (1) a fine powder of a water-insoluble polymer or (2) a fine powder of a water-insoluble polymer and at least one member selected from the group consisting of talc, magnesium stearate and titanium oxide.Type: GrantFiled: February 20, 2003Date of Patent: April 19, 2011Assignee: Otsuka Pharmaceutical Co., Ltd.Inventor: Tomohira Yuso
-
Patent number: 7923029Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.Type: GrantFiled: April 10, 2003Date of Patent: April 12, 2011Assignee: MedImmune LLCInventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
-
Publication number: 20110076337Abstract: The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices.Type: ApplicationFiled: September 30, 2010Publication date: March 31, 2011Inventors: Joram Slager, Aleksey V. Kurdyumov, Dale G. Swan
-
Patent number: 7910132Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: GrantFiled: October 10, 2006Date of Patent: March 22, 2011Assignee: Orexo ABInventors: Anders Pettersson, Christer Nystrom
-
Publication number: 20110064665Abstract: The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a hybrid gold/gold sulfide nanoparticle with a chitosan matrix surrounding the metallic nanoparticle and a method for making the same. The chitosan-coated gold/gold sulfide nanoparticles can then be incorporated with additional therapeutic or diagnostic compounds such as iodine, antibodies, or other suitable compounds. The nanoparticles of the present invention have the dual capabilities of absorbing near infrared wavelength light to (1) act as a therapeutic agent by generating heat energy effective for cell ablation or for release of therapeutic compounds embedded in the chitosan matrix and (2) creating diagnostic benefit by incorporation of X-ray or MRI contrast agents.Type: ApplicationFiled: September 14, 2010Publication date: March 17, 2011Inventors: Andre' M. Gobin, Guandong Zhang
-
Publication number: 20110064676Abstract: The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a hybrid gold/gold sulfide nanoparticle with a chitosan matrix surrounding the metallic nanoparticle and a method for making the same. The chitosan-coated gold/gold sulfide nanoparticles can then be incorporated with additional therapeutic or diagnostic compounds such as iodine, antibodies, or other suitable compounds. The nanoparticles of the present invention have the dual capabilities of absorbing near infrared wavelength light to (1) act as a therapeutic agent by generating heat energy effective for cell ablation or for release of therapeutic compounds embedded in the chitosan matrix and (2) creating diagnostic benefit by incorporation of X-ray or MRI contrast-agents.Type: ApplicationFiled: September 14, 2010Publication date: March 17, 2011Inventors: Andre' M. Gobin, Guandong Zhang
-
Patent number: 7906333Abstract: A surface modification method of polysaccharide, the modified polysaccharide, and a method of culturing and recovery cells using the same are provided. The surface modification method of polysaccharide comprises (a) immersing a polysaccharide material in an acid, (b) immersing the polysaccharide material in an acidic solution containing a protein, and (c) immersing the polysaccharide material in an alkaline solution containing bivalent metal ions.Type: GrantFiled: March 21, 2006Date of Patent: March 15, 2011Assignee: Industrial Technology Research InstituteInventors: Chun-Jen Liao, Yung-chih Wu, Chen-Chi Tsai, Hsiang-Ming Huang, Yuan-Hua Hsu, Shu-Fang Chiang
-
Publication number: 20110052713Abstract: The present application relates to reduction of acrolein-mediated cell death following neural insult. According to at least one embodiment, chitosan is utilized as a membrane fusogen to restore cell function. According to at least one other embodiment, chitosan or silica is used to create a non-toxic polymer surfaced microcolloid (PSM). PSMs were found to preferentially target the damaged nerve tissues; to restore conduction of nerve impulses; to seal/restore nerve fiber membranes; and to reduce to baseline the efflux of a large intracellular enzyme. PSMs are further used as a drug delivery vehicle for acrolein scavengers including hydralazine.Type: ApplicationFiled: January 16, 2009Publication date: March 3, 2011Inventors: Youngnam Cho, Riyi Shi, Albena Ivanslevic, Richard Borgens
-
Publication number: 20110052709Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.Type: ApplicationFiled: November 10, 2010Publication date: March 3, 2011Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: James W. Lillard, Rajesh Singh, Shailesh Singh
-
Publication number: 20110052710Abstract: Milled nanoparticles comprising a biologically active agent, at least one biopolymer and a coating containing at least one coating which is a polymer or ligand are produced using milling and coating techniques which have not previously been used for these applications.Type: ApplicationFiled: November 10, 2010Publication date: March 3, 2011Applicant: MOREHOUSE SCHOOL OF MEDICINEInventors: James W. LILLARD, Rajesh Singh, Shailesh Singh
-
Publication number: 20110052711Abstract: A controlled release multidrug formulation for improving locomotor recovery after spinal cord injury comprising: (a) a first composition comprising a first bioactive agent, encapsulated within a first polymeric particle; (b) a second composition comprising a second bioactive agent, encapsulated within a second polymeric particle, wherein the second polymeric particle is encapsulated within the first polymeric particle; and (c) a third composition comprising a third bioactive agent, encapsulated within either the first or the second polymeric particle, wherein the second composition is released subsequently to the release of the first composition, and wherein the first bioactive agent is a neurotrophic factor, the second bioactive agent is a collagen synthesis inhibitor, and the third bioactive agent is selected from the group consisting of cyclic AMP (cAMP), an adenylate cyclase activator and a Rho inhibitor.Type: ApplicationFiled: August 27, 2009Publication date: March 3, 2011Applicant: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Yu-Chao Wang, Yi-Ting Wu, Chung-Shi Yang
-
Publication number: 20110052712Abstract: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.Type: ApplicationFiled: February 12, 2010Publication date: March 3, 2011Inventors: Donald J. Eaton, Bin Huang, Michael A. Savitt
-
Patent number: 7897177Abstract: A particulate fiber composition containing at least one first dietary fiber, coated by an insoluble dietary fiber or a dietary fiber with low solubility, serving to prevent dissolution of the fiber composition in the oral cavity and during passage through the esophagus. The fiber composition has one or several inserted additional layers of at least one second dietary fiber between the at least one first dietary fiber and the coating of the insoluble dietary fiber/dietary fiber of low solubility. The different properties of solubility and fermentability of the fibers are utilized for the production of multilayer particles. The dietary fiber composition can be used as a supplement applied in pharmaceuticals and food products where high fiber content and small calorie content is given a high priority. Furthermore, the dietary fiber supplement can be applied for replacement of part of the sugar in sugar coatings of generally known cereals.Type: GrantFiled: October 19, 2004Date of Patent: March 1, 2011Assignee: Medic House Cambrige LtdInventors: Lasse L. Hessel, Jesper Malling, Eivind Gudmand-Høyer
-
Patent number: 7892599Abstract: Methods for functionalizing the surface of nanomaterials to improve processing and product manufacturing. These methods are useful for oxides, nitrides, carbides, borides, metals, alloys, chalcogenides, and other compositions.Type: GrantFiled: July 27, 2004Date of Patent: February 22, 2011Assignee: PPG Industries Ohio, Inc.Inventors: Tapesh Yadav, Karl Pfaffenbach
-
Publication number: 20110038940Abstract: A pulverulent composition includes less than 96% in weight, preferably from 10 to 80%, and more preferably from 20% to 70%, of at least a vitamin having a solubility lower than 20 g/L and preferably 1 g/L and more preferably lower than 500 mg/L in aqueous media, the pulverulent composition being stable on storage and having instantaneous dispersion and solubility properties in aqueous solutions.Type: ApplicationFiled: February 6, 2009Publication date: February 17, 2011Applicant: INNOV'IAInventor: Alain Grizeau
-
Publication number: 20110038931Abstract: The present invention provides a combination preparation which comprises: a prior-release section comprising aspirin or a pharmaceutically acceptable salt thereof as a pharmacologically active component; and a delayed-release section comprising clopidogrel, an isomer thereof or a pharmaceutically acceptable salt thereof as a pharmacologically active component. The combination preparation of the present invention exhibits a far better effect in preventing platelet aggregation than does simultaneous oral therapy or treatment with the respective single preparations, and not only can it improve the patient's drug-taking compliance by administration once a day but it can also reduce the adverse reactions which follow long-term administration of aspirin.Type: ApplicationFiled: February 21, 2009Publication date: February 17, 2011Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Young Gwan Jo, Ja Seong Koo, Sang Ouk Sun, Jung-won Bae
-
Patent number: 7883723Abstract: The present invention relates to a water soluble chitosan nanoparticle (WSC-NP) for delivering an anticancer agent and a preparing method thereof, more precisely, a water soluble chitosan nanoparticle for delivering an anticancer agent which has function of targeting on a wanted area by introducing a functional group in the location of highly reactive amine group and becomes an excellent gene carrier with the use of water soluble chitosan since the water soluble chitosan itself can combined with DNA having a negative electric charge(?) owing to the very strong positive electric charge(+) of its amine group, and a preparing method thereof. Therefore, a water-soluble chitosan nanoparticle for delivering an anticancer agent of the present invention can effectively envelope paclitaxel by introducing hydrophilic and hydrophobic groups in the position of highly reactive amine group of the water-soluble chitosan.Type: GrantFiled: May 13, 2005Date of Patent: February 8, 2011Inventors: Jae-Woon Nah, Teok Rae Jung, Mi-Kyeong Jang, Young-Il Jeong
-
Publication number: 20110027174Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.Type: ApplicationFiled: October 15, 2010Publication date: February 3, 2011Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Birls, Richard Beger
-
Patent number: 7879362Abstract: The invention concerns a galenic system with prolonged/controlled release of the medicinal and/or nutritional active principle, for oral administration. The aim is to provide a system enabling to obtain with one single tolerable and acceptable dose of active principle, efficient therapeutic protection over 24 hours (increasing the bioabsorption time without affecting bioavailability).Type: GrantFiled: March 21, 2007Date of Patent: February 1, 2011Assignee: Flamel TechnologiesInventors: Catherine Castan, Valerie Legrand, Rémi Meyrueix, Gérard Soula
-
Patent number: 7863256Abstract: The present invention concerns amide derivatives of hyaluronic acid (HA) and biomaterials made of amide derivatives of hyaluronic acid (HA), particularly the hexadecylamide of HA, administered by the intra-articular route as a partial/total substitute for synovial fluid to treat joints affected by osteoarthrosis (OA) as well as cases of joint inflammation and/or trauma that cause damage to the cartilage and/or synovia (associated with pain). Lastly, we describe and claim their use in the treatment of joints where the entire structure shows signs of wear due to physiological aging.Type: GrantFiled: February 20, 2006Date of Patent: January 4, 2011Assignee: Fidia Farmaceutici S.p.A.Inventors: Antonella Schiavinato, Davide Bellini
-
Publication number: 20100330188Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material in the powder has been found to give an increased respirable fraction of the active material.Type: ApplicationFiled: March 26, 2010Publication date: December 30, 2010Applicant: Vectura LimitedInventor: John Nicholas Staniforth
-
Publication number: 20100330137Abstract: The present invention relates to a pharmaceutical or dietary composition containing Mangosteen (Garcinia Mangostana pericarp) and being characterized by high bioavailability. A process for the manufacture of this composition is a further object of the present invention. In particular, the present invention relates to a composition containing Mangosteen extract and oligosaccharides in an amount ranging from 5 to 50 w/w % with respect to the Mangosteen extract or a fermented Mangosteen product and to a process for obtaining thereof.Type: ApplicationFiled: March 10, 2008Publication date: December 30, 2010Inventor: Mauro Mantovani
-
Patent number: 7842658Abstract: The invention describes a stable and transparent liquid washing agent or liquid cleaning agent having a graying-inhibiting polysaccharide that has a particle size smaller than 100 nm. The invention also relates to the use of the liquid washing agent or liquid cleaning agent, and to a method for the manufacture thereof.Type: GrantFiled: November 5, 2009Date of Patent: November 30, 2010Assignee: Henkel AG & Co. KGaAInventors: Bernhard Guckenbiehl, Sören Hölsken, Carine Wattebled